AttoDx, Inc.

Medtech · Defunct

Molecular viability testing (MVT) system—a pre-PCR sample preparation unit that enhances bacterial detection sensitivity in PCR-based diagnostics

attodx.com →
Grants
$220K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Ultra-Sensitive Diagnosis of AIDS-Related Tuberculosis$220,230
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
791Innovative Biotherapies, Inc.——
792SAFETYSPECT, INC.—$106K
793KoKo Medical, Inc.—$27M
794AttoDx, Inc.——
795IMGGYD LLC——
796Vektor Medical, Inc.—$33M
797SENSYDIA CORPORATION—$16M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.